Nektar Therapeutics (NKTR)

[SeriousMoney]

So does ChangeWave Biotech Investor - 7/13/06

NEKTAR (NKTR): Exubera, its inhaled insulin product marketed by Pfizer, should be available in the U.S. within days and the debate has begun with the naysayers winning the battle in the press.

Ignore them!

Very recent ChangeWave Alliance survey results show Exubera is going to do very, very well, especially with new insulin-using patients. I will share final data with you next week. The stock is holding up very well at around $17 and is at an excellent entry point. You can expect the positive stories will start hitting the press sometime in the next few weeks.